Biotechnology company · EXEL

Exelixis
clinical trial
pipeline

Registry checked

Published

Zanzalintinib is linked to 10 distinct active studies, with 4 Phase 1, 1 Phase 2, 5 Phase 3. cabozantinib is linked to 6 distinct active studies, with 1 Phase 1, 5 Phase 3.

Phase 3 study NCT05678673 in Non-Clear Cell Renal Cell Carcinoma lists estimated primary completion on 15 December 2026. These are registry estimates of primary completion, not confirmed results announcements or overall study completion.

Active trial mix

Lead-sponsor scope

22active trials
as lead sponsor
  • Phase 19
  • Phase 22
  • Phase 310
  • Phase 41
  • Phase not recorded0

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

02 Oct 2026 – 31 Oct 2026 · UTC

Recorded changes

00 trials30 completed days

No eligible observations recorded in this period.

Recruitment statusPrimary completionEnrolmentFirst observedOther

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-020000000
2026-10-030000000
2026-10-040000000
2026-10-050000000
2026-10-060000000
2026-10-070000000
2026-10-080000000
2026-10-090000000
2026-10-100000000
2026-10-110000000
2026-10-120000000
2026-10-130000000
2026-10-140000000
2026-10-150000000
2026-10-160000000
2026-10-170000000
2026-10-180000000
2026-10-190000000
2026-10-200000000
2026-10-210000000
2026-10-220000000
2026-10-230000000
2026-10-240000000
2026-10-250000000
2026-10-260000000
2026-10-270000000
2026-10-280000000
2026-10-290000000
2026-10-300000000
2026-10-310000000
Type totals0000000 distinct

02 / Drugs & programmes

Explore the pipeline

6 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

Zanzalintinib

Canonical investigational asset

10
Active trials
5
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 14
  • Phase 21
  • Phase 35
  • Phase 40
  • Phase not recorded0
Studied condition
Cancer · Clear Cell Renal Cell Carcinoma (ccRCC) · Colorectal Cancer
Next primary completion
15 December 2026 · estimated
Open drug

cabozantinib

Canonical investigational asset

6
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 11
  • Phase 20
  • Phase 35
  • Phase 40
  • Phase not recorded0
Studied condition
Cancer · Castration-resistant Prostate Cancer · Colorectal Cancer
Next primary completion
Not reported
Open drug

Cabozantinib (XL184) 140 mg

Canonical investigational asset

1
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 20
  • Phase 30
  • Phase 41
  • Phase not recorded0
Studied condition
Medullary Thyroid Cancer
Next primary completion
Not reported
Open drug

Carboplatin

kyxata

1
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 2
  • Phase 10
  • Phase 21
  • Phase 30
  • Phase 40
  • Phase not recorded0
Studied condition
Squamous Non-Small Cell Lung Cancer (NSCLC)
Next primary completion
Not reported
Open drug

XB010

Canonical investigational asset

1
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 1
  • Phase 11
  • Phase 20
  • Phase 30
  • Phase 40
  • Phase not recorded0
Studied condition
Esophageal Squamous Cell Cancer · Head and Neck Squamous Cell Cancer · Hormone-receptor-positive Breast Cancer
Next primary completion
Not reported
Open drug

XB371

Canonical investigational asset

1
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 1
  • Phase 11
  • Phase 20
  • Phase 30
  • Phase 40
  • Phase not recorded0
Studied condition
Solid Tumors
Next primary completion
Not reported
Open drug

22 of 22 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

6 selected programmes · accepted investigational links cover 22 of 22 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

Exelixis trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
6 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
STELLAR-304
Zanzalintinib

NCT05678673

Phase 3 · Active, not recruiting

Trial source and qualifications

Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 3 inspected observations were not displayed.

4 candidate observations · 1 shown · 0 recorded after primary completion · 3 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

3 inspected observations omitted. At most three verified observations are shown, not full history.

  • pc date moved · Recorded 2026-07-29 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

Start: 01 Jan 2023 · actual
Primary completion: 15 Dec 2026 · estimated
Study completion: 30 Jun 2028 · estimated

2021202220232024202520262027202820292030
STELLAR-201
Zanzalintinib

NCT07428616

Phase 2 · Recruiting

Trial source and qualifications

A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

1 inspected observations omitted. At most three verified observations are shown, not full history.

    Start: 21 May 2026 · actual
    Primary completion: 29 Feb 2028 · estimated
    Study completion: 30 Sept 2029 · estimated

    2021202220232024202520262027202820292030
    STELLAR-202
    Carboplatin

    NCT07845786

    Phase 2 · Not yet recruiting

    Trial source and qualifications

    Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

    1 candidate observations · 0 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 1 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    1 inspected observations omitted. At most three verified observations are shown, not full history.

      Start: 15 Dec 2026 · estimated
      Primary completion: 15 Jun 2028 · estimated
      Study completion: 15 Jun 2030 · estimated

      2021202220232024202520262027202820292030
      STELLAR-305
      Zanzalintinib

      NCT06082167

      Phase 3 · Active, not recruiting

      Trial source and qualifications

      Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 4 inspected observations were not displayed.

      4 candidate observations · 0 shown · 0 recorded after primary completion · 4 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      4 inspected observations omitted. At most three verified observations are shown, not full history.

        Start: 07 Jun 2024 · actual
        Primary completion: Aug 2028 · estimated
        Study completion: Mar 2029 · estimated

        2021202220232024202520262027202820292030
        STELLAR-311
        Zanzalintinib

        NCT06943755

        Phase 3 · Recruiting

        Trial source and qualifications

        Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

        0 candidate observations · 0 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        No eligible observations recorded in the inspected period.

          Start: 21 Jul 2025 · actual
          Primary completion: 30 Jun 2029 · estimated
          Study completion: 30 Jun 2029 · estimated

          2021202220232024202520262027202820292030
          STELLAR-316
          Zanzalintinib

          NCT07750158

          Phase 3 · Recruiting

          Trial source and qualifications

          Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease

          Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

          2 candidate observations · 1 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 1 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

          ClinicalTrials.gov source

          1 inspected observations omitted. At most three verified observations are shown, not full history.

          • status flip · Recorded 2026-09-21 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

          Start: 25 Aug 2026 · estimated
          Primary completion: 05 Apr 2030 · estimated
          Study completion: 05 Apr 2030 · estimated

          2021202220232024202520262027202820292030

          Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

          6 selected of 7 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 5 actual primary completions, 0 untyped primary completions, 0 past estimates, 0 outside the horizon, 0 contradictory dates.

          04 / Therapeutic focus

          Where the activity is

          20

          active trials in Oncology

          Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

          Active trials by primary therapeutic area

          • Oncology20 trials
          • Gastroenterology & Hepatology1 trials
          • Unmapped1 trials
          • Healthy volunteers0 trials

          Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

          06 / Related companies

          All companies
          R

          Roche

          Shared indexed programme context · 2 selected assets

          A

          AbbVie

          Shared indexed programme context · 1 selected asset

          A

          Amgen

          Shared indexed programme context · 1 selected asset

          Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

          Sources, scope and methodology

          ClinicalTrials.gov lead-sponsor scope

          Canonical current-owner attribution covers 57 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: Exelixis. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion.

          ClinicalTrials.gov

          Attribution coverage

          57 distinct registry candidates produced 57 accepted studies. 0 mapped to other owners, 0 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 0 unverified, 0 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

          Indexed enrichment

          56 scoped records have indexed enrichment and 1 do not. Missing enrichment does not remove a trial from cohort counts.

          Scope observation

          The successful attribution check completed at 2026-11-01T06:31:09.641Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot 2efd5f558fbc5c326c3417b4a4cc3fb073b4679b521cf09771cf68b210807d9d.

          Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

          Dated canonical-attribution snapshot: 57 mapped lead-sponsored clinical studies across all statuses. 56 have indexed enrichment, 1 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

          Keep following
          what matters.

          Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

          Build your watch

          Choose what to track in the watch builder.